No Data
No Data
Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $13
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $7
Express News | Leerink Partners Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $13
A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $7 to $10
The 11% Return This Week Takes Aquestive Therapeutics' (NASDAQ:AQST) Shareholders One-year Gains to 289%
Aquestive Therapeutics' Breakthrough in Allergy Treatment Study